Related Experiment Videos
Magnetite albumin microspheres: a new MR contrast material
Abstract:
A superparamagnetic MR contrast agent was synthesized by incorporating 150-250-A particles of magnetite (Fe3O4, Fe2O3) in 1-5 microns human serum albumin microspheres. Magnetite albumin microspheres (MAM) target almost exclusively to the reticuloendothelial system after IV administration, are stable in vitro and in vivo, and possess a long shelf life. The agent has a large magnetic susceptibility effect that selectively reduces T2 with little effect on T1. Biodistribution studies that use a dose of 20 mg MAM/kg show prompt clearance from the blood pool with marked decrease in T2 for rat liver (40%) and spleen (45%) with a small decrease in liver (5%) and spleen (10%) T1 values. Pulmonary T1 and T2 decrease transiently over the first 24 hr, while no significant changes were observed in other tissues. Imaging of a rabbit VX2 tumor model resulted in a 200% increase in the contrast ratio of VX2 tumor to normal liver on T2-weighted and mixed T1-/T2-weighted pulse sequences after administration of contrast agent. The extreme potency, excellent targeting, and apparent lack of toxicity of this agent suggest that MAM probably will have a clinical application in detecting focal hepatic and splenic lesions.
Insights
Magnetite albumin microspheres (MAM) offer a novel superparamagnetic MRI contrast agent. These microspheres show excellent targeting to the liver and spleen, enhancing tumor detection with minimal toxicity.
Area of Science:
- Biomedical Engineering
- Materials Science
- Radiology
Background:
- Development of effective MRI contrast agents is crucial for accurate disease diagnosis.
- Superparamagnetic iron oxide nanoparticles offer unique magnetic properties for MRI.
Purpose of the Study:
- To synthesize and characterize a novel superparamagnetic MRI contrast agent using magnetite albumin microspheres (MAM).
- To evaluate the biodistribution, stability, and efficacy of MAM for lesion detection in vivo.
Main Methods:
- Synthesis of 150-250 Å magnetite (Fe3O4, Fe2O3) particles within 1-5 μm human serum albumin microspheres.
- In vitro and in vivo stability assessments.
- Biodistribution studies in rats following IV administration (20 mg MAM/kg).
- MRI imaging of a rabbit VX2 tumor model using T2-weighted and mixed T1-/T2-weighted sequences.
Main Results:
- MAM demonstrated selective T2 reduction with minimal T1 effect.
- Rapid blood clearance and significant T2 reduction in rat liver (40%) and spleen (45%).
- Transient pulmonary T1 and T2 changes within 24 hours, with no significant effects in other tissues.
- 200% increase in contrast ratio for VX2 tumors in rabbits, improving lesion visualization.
Conclusions:
- Magnetite albumin microspheres (MAM) are a potent, stable, and non-toxic superparamagnetic MRI contrast agent.
- MAM exhibits excellent targeting to the reticuloendothelial system, particularly the liver and spleen.
- The agent shows significant potential for clinical application in detecting focal hepatic and splenic lesions.